• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.M1毒蕈碱型乙酰胆碱受体的选择性变构增强剂可增加内侧前额叶皮质神经元的活性,并恢复逆向学习中的损伤。
J Neurosci. 2009 Nov 11;29(45):14271-86. doi: 10.1523/JNEUROSCI.3930-09.2009.
2
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.通过变构增强实现对M1毒蕈碱型乙酰胆碱受体的选择性激活。
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. doi: 10.1073/pnas.0900903106. Epub 2009 Aug 26.
3
Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication.使用毒蕈碱型 M1 受体正变构调节剂通过增强脑内胆碱能通讯来改善记忆。
Eur J Pharmacol. 2012 Dec 15;697(1-3):73-80. doi: 10.1016/j.ejphar.2012.10.011. Epub 2012 Oct 17.
4
Probing the binding site of novel selective positive allosteric modulators at the M muscarinic acetylcholine receptor.探究新型选择性正变构调节剂在 M 型毒蕈碱乙酰胆碱受体上的结合位点。
Biochem Pharmacol. 2018 Aug;154:243-254. doi: 10.1016/j.bcp.2018.05.009. Epub 2018 May 17.
5
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.新型 M1 毒蕈碱型乙酰胆碱受体变构激动剂诱导出与动物模型中的行为效应相对应的脑区特异性反应。
J Neurosci. 2012 Jun 20;32(25):8532-44. doi: 10.1523/JNEUROSCI.0337-12.2012.
6
M-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition.不具有激动剂活性的 M 型正变构调节剂为增强认知提供了最佳的作用模式。
Neuropsychopharmacology. 2018 Jul;43(8):1763-1771. doi: 10.1038/s41386-018-0033-9. Epub 2018 Mar 14.
7
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice.M1毒蕈碱型乙酰胆碱受体在小鼠使用触摸屏视觉辨别任务的自上而下认知加工中的作用
ACS Chem Neurosci. 2015 Oct 21;6(10):1683-95. doi: 10.1021/acschemneuro.5b00123. Epub 2015 Aug 5.
8
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.新型M1毒蕈碱型乙酰胆碱受体选择性变构激活剂可调节淀粉样蛋白加工并在大鼠中产生抗精神病样活性。
J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008.
9
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M PAM VU6004256.在NMDA受体功能减退的遗传模型中,前额叶皮质介导的损伤被新型M PAM VU6004256逆转。
ACS Chem Neurosci. 2016 Dec 21;7(12):1706-1716. doi: 10.1021/acschemneuro.6b00230. Epub 2016 Oct 5.
10
Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.M1 毒蕈碱型乙酰胆碱受体变构调节的分子决定因素。
J Biol Chem. 2014 Feb 28;289(9):6067-79. doi: 10.1074/jbc.M113.539080. Epub 2014 Jan 17.

引用本文的文献

1
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.毒蕈碱M型正变构调节剂VU0467319用于阿尔茨海默病的安全性、耐受性、药代动力学和药效学效应:一项在健康受试者中的单剂量递增研究
Alzheimers Res Ther. 2025 Jul 1;17(1):144. doi: 10.1186/s13195-025-01798-4.
2
Downstream Signaling of Muscarinic M Receptors Is Regulated by Receptor Density and Cellular Environment.毒蕈碱型M受体的下游信号传导受受体密度和细胞环境的调节。
Pharmacol Res Perspect. 2025 Jun;13(3):e70123. doi: 10.1002/prp2.70123.
3
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy Participants.毒蕈碱M1型正变构调节剂VU0467319用于阿尔茨海默病的安全性、耐受性、药代动力学和药效学效应:一项在健康受试者中的单剂量递增研究
Res Sq. 2025 Apr 4:rs.3.rs-6271510. doi: 10.21203/rs.3.rs-6271510/v1.
4
A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse.毒蕈碱型乙酰胆碱受体调节剂在神经疾病、癌症和药物滥用领域的新时代。
Pharmaceuticals (Basel). 2025 Mar 5;18(3):369. doi: 10.3390/ph18030369.
5
Application of Deuterium in an M Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422.氘在M阳性变构调节剂后备项目中的应用:VU6045422的发现
ACS Chem Neurosci. 2025 Apr 16;16(8):1582-1591. doi: 10.1021/acschemneuro.5c00119. Epub 2025 Mar 25.
6
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.从理论到治疗:通过双重 M1/M4 毒蕈碱受体激动剂 xanomeline 和氯化曲司氯铵释放毒蕈碱受体激活在精神分裂症中的潜力及临床试验见解
Int J Neuropsychopharmacol. 2025 Apr 11;28(4). doi: 10.1093/ijnp/pyaf015.
7
AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist.AiGPro:一种用于G蛋白偶联受体激动剂和拮抗剂分析的多任务模型。
J Cheminform. 2025 Jan 29;17(1):12. doi: 10.1186/s13321-024-00945-7.
8
Discovery of VU0467319: an M Positive Allosteric Modulator Candidate That Advanced into Clinical Trials.VU0467319的发现:一种进入临床试验的M阳性变构调节剂候选物。
ACS Chem Neurosci. 2025 Jan 1;16(1):95-107. doi: 10.1021/acschemneuro.4c00769. Epub 2024 Dec 11.
9
Discovery of VU6007496: Challenges in the Development of an M Positive Allosteric Modulator Backup Candidate.VU6007496 的发现:M 阳性变构调节剂候补药物开发所面临的挑战。
ACS Chem Neurosci. 2024 Sep 18;15(18):3421-3433. doi: 10.1021/acschemneuro.4c00508. Epub 2024 Aug 28.
10
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.神经退行性疾病中毒蕈碱型乙酰胆碱受体调节的黄金时代。
Nat Rev Drug Discov. 2024 Oct;23(10):743-758. doi: 10.1038/s41573-024-01007-1. Epub 2024 Aug 14.

本文引用的文献

1
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.通过变构增强实现对M1毒蕈碱型乙酰胆碱受体的选择性激活。
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. doi: 10.1073/pnas.0900903106. Epub 2009 Aug 26.
2
Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.首个高度偏好M5的毒蕈碱型乙酰胆碱受体配体的发现,一种源自一系列5-三氟甲氧基N-苄基异吲哚酮的M5正变构调节剂。
J Med Chem. 2009 Jun 11;52(11):3445-8. doi: 10.1021/jm900286j.
3
A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning.一种新型选择性毒蕈碱型乙酰胆碱受体1亚型拮抗剂可减少癫痫发作,且不损害海马体依赖性学习。
Mol Pharmacol. 2009 Aug;76(2):356-68. doi: 10.1124/mol.109.056531. Epub 2009 Apr 30.
4
M1 agonists as a potential disease-modifying therapy for Alzheimer's disease.M1 激动剂作为阿尔茨海默病潜在的疾病修饰疗法。
Curr Alzheimer Res. 2009 Apr;6(2):112-7. doi: 10.2174/156720509787602915.
5
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.用于治疗中枢神经系统疾病的毒蕈碱受体亚型选择性变构调节剂。
Trends Pharmacol Sci. 2009 Mar;30(3):148-55. doi: 10.1016/j.tips.2008.12.002. Epub 2009 Feb 7.
6
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.G蛋白偶联受体的变构调节剂:一种治疗中枢神经系统疾病的新方法。
Nat Rev Drug Discov. 2009 Jan;8(1):41-54. doi: 10.1038/nrd2760.
7
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.M1毒蕈碱受体新型变构增强剂的发现与表征揭示了多种活性模式。
Mol Pharmacol. 2009 Mar;75(3):577-88. doi: 10.1124/mol.108.052886. Epub 2008 Dec 1.
8
Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.乙酰胆碱酯酶抑制剂作为阿尔茨海默病的疾病修饰疗法。
Curr Med Chem. 2008;15(24):2433-55. doi: 10.2174/092986708785909067.
9
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.新型M1毒蕈碱型乙酰胆碱受体选择性变构激活剂可调节淀粉样蛋白加工并在大鼠中产生抗精神病样活性。
J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008.
10
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.M4毒蕈碱型乙酰胆碱受体的中枢活性变构增强剂可逆转苯丙胺诱导的大鼠运动活动亢进。
J Pharmacol Exp Ther. 2008 Dec;327(3):941-53. doi: 10.1124/jpet.108.140350. Epub 2008 Sep 4.

M1毒蕈碱型乙酰胆碱受体的选择性变构增强剂可增加内侧前额叶皮质神经元的活性,并恢复逆向学习中的损伤。

A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

作者信息

Shirey Jana K, Brady Ashley E, Jones Paulianda J, Davis Albert A, Bridges Thomas M, Kennedy J Phillip, Jadhav Satyawan B, Menon Usha N, Xiang Zixiu, Watson Mona L, Christian Edward P, Doherty James J, Quirk Michael C, Snyder Dean H, Lah James J, Levey Allan I, Nicolle Michelle M, Lindsley Craig W, Conn P Jeffrey

机构信息

Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6600, USA.

出版信息

J Neurosci. 2009 Nov 11;29(45):14271-86. doi: 10.1523/JNEUROSCI.3930-09.2009.

DOI:10.1523/JNEUROSCI.3930-09.2009
PMID:19906975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2811323/
Abstract

M(1) muscarinic acetylcholine receptors (mAChRs) may represent a viable target for treatment of disorders involving impaired cognitive function. However, a major limitation to testing this hypothesis has been a lack of highly selective ligands for individual mAChR subtypes. We now report the rigorous molecular characterization of a novel compound, benzylquinolone carboxylic acid (BQCA), which acts as a potent, highly selective positive allosteric modulator (PAM) of the rat M(1) receptor. This compound does not directly activate the receptor, but acts at an allosteric site to increase functional responses to orthosteric agonists. Radioligand binding studies revealed that BQCA increases M(1) receptor affinity for acetylcholine. We found that activation of the M(1) receptor by BQCA induces a robust inward current and increases spontaneous EPSCs in medial prefrontal cortex (mPFC) pyramidal cells, effects which are absent in acute slices from M(1) receptor knock-out mice. Furthermore, to determine the effect of BQCA on intact and functioning brain circuits, multiple single-unit recordings were obtained from the mPFC of rats that showed BQCA increases firing of mPFC pyramidal cells in vivo. BQCA also restored discrimination reversal learning in a transgenic mouse model of Alzheimer's disease and was found to regulate non-amyloidogenic APP processing in vitro, suggesting that M(1) receptor PAMs have the potential to provide both symptomatic and disease modifying effects in Alzheimer's disease patients. Together, these studies provide compelling evidence that M(1) receptor activation induces a dramatic excitation of PFC neurons and suggest that selectively activating the M(1) mAChR subtype may ameliorate impairments in cognitive function.

摘要

M(1)型毒蕈碱型乙酰胆碱受体(mAChRs)可能是治疗认知功能受损相关疾病的一个可行靶点。然而,检验这一假设的一个主要限制是缺乏针对单个mAChR亚型的高选择性配体。我们现在报告一种新型化合物苄基喹诺酮羧酸(BQCA)的严格分子特征,它是大鼠M(1)受体的一种强效、高选择性正变构调节剂(PAM)。该化合物不直接激活受体,而是作用于变构位点以增强对正构激动剂的功能反应。放射性配体结合研究表明,BQCA增加了M(1)受体对乙酰胆碱的亲和力。我们发现,BQCA激活M(1)受体可诱导强大的内向电流,并增加内侧前额叶皮质(mPFC)锥体细胞中的自发性兴奋性突触后电流(EPSCs),而在M(1)受体基因敲除小鼠的急性脑片中则没有这些效应。此外,为了确定BQCA对完整且功能正常的脑回路的影响,我们从大鼠的mPFC获得了多个单单位记录,结果显示BQCA在体内增加了mPFC锥体细胞的放电。BQCA还恢复了阿尔茨海默病转基因小鼠模型中的辨别逆转学习能力,并且在体外发现它可调节非淀粉样前体蛋白(APP)的加工,这表明M(1)受体PAM有潜力在阿尔茨海默病患者中提供症状缓解和疾病修饰作用。总之,这些研究提供了令人信服的证据,表明M(1)受体激活可诱导PFC神经元的显著兴奋,并表明选择性激活M(1) mAChR亚型可能改善认知功能障碍。